Sensible Diagnostics
Sensible Diagnostics is a privately held diagnostics-sector entity whose only observable public presence is a placeholder 'Under Construction' website, with no disclosed products, technology, customers, or revenue model in the source data.
- Company typePrivate
- Founded-
- HeadquartersLos Angeles, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Sensible Diagnostics does
Sensible Diagnostics is a privately held entity whose name suggests operations in the diagnostics sector, though no substantive business information is available in the source data reviewed. The company's only observable public-facing presence is a Google Sites placeholder page at sensibledx.com marked 'Under Construction,' containing no product descriptions, technology disclosures, team information, customer references, or pricing details. No products or services have been documented; no core technology stack, proprietary features, or platform architecture is described in the source material. The source data includes empty arrays for headcount, funding rounds, partnerships, certifications, awards, patents, management team, and M&A activity, indicating either an early-stage profile or a complete absence of disclosed information.
The company's business model cannot be characterized from the available data: no revenue model, pricing approach, go-to-market motion, distribution channels, or customer segmentation is disclosed. The legal entity name 'Sensible Diagnostics' is confirmed and the company is presumed private based on absence of public listing evidence. Operating status is marked as 'operating' per the source, though the 'Under Construction' website state introduces ambiguity — it may reflect an early-stage website build rather than company inactivity. Ownership, domicile, founding date, and geographic operating footprint are all undisclosed in the available material.
Sensible Diagnostics firmographics
Firmographics- Name
- Sensible Diagnostics
- Legal name
- Sensible Diagnostics
- Website
- https://sensibledx.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Sensible Diagnostics is a privately held diagnostics-sector entity whose only observable public presence is a placeholder 'Under Construction' website, with no disclosed products, technology, customers, or revenue model in the source data.
- Ownership category
- akta.pro rank
Sensible Diagnostics industry classification
Industry- Product category
- Clinical Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- akta.pro primary industry
- Method Development & Validation (ICH/USP) (HLAGADAB)
Keywords
Where Sensible Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Los Angeles
- HQ country
- United States
- HQ region
- North America
Markets served
Sensible Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Services
Sensible Diagnostics product offering
Product offeringCore offering
The company's core offerings cannot be determined from the available source data. The sourced material consists of a Google Sites placeholder page displaying an 'Under Construction' notice with no substantive product, service, or capability information. The company name 'Sensible Diagnostics' suggests an orientation toward diagnostic products, but no specific products or services are described in the input.
Differentiator
Problem solved
Functional benefit
Sensible Diagnostics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Sensible Diagnostics partnerships and signals
Strategic signalRecent moves1 record
Expansion highlights1 record
Sensible Diagnostics competitors and assessment
Company assessmentBroad incumbents
- Cepheid: Cepheid (a Danaher subsidiary) is a leading molecular diagnostics company with the GeneXpert platform widely deployed in clinical and point-of-care settings. Comparable to a company named Sensible Diagnostics as a benchmark for in-vitro diagnostics product economics, regulatory pathway, and hospital-channel commercialization.
- bioMérieux: bioMérieux is a global in-vitro diagnostics leader across clinical and industrial microbiology, immunoassays, and molecular diagnostics. It is a relevant incumbent benchmark for any company entering diagnostics with respect to menu breadth, regulatory scale, and global distribution.
- QuidelOrtho: QuidelOrtho specializes in clinical diagnostics, including rapid immunoassays and molecular testing. It is comparable to Sensible Diagnostics as a mid-sized diagnostics player addressing similar hospital and point-of-care customers with assay-based products.
- Hologic: Hologic's Diagnostics segment produces molecular assays (e.g., Panther system) and rapid tests across women's health, infectious disease, and respiratory. Comparable as a clinical diagnostics incumbent with a similar assay-based business model and FDA-cleared product portfolio.
- Abbott Diagnostics: Abbott is a top-tier diagnostics company with platforms spanning immunoassays, clinical chemistry, molecular, and rapid point-of-care testing (e.g., Binax, ID NOW). Comparable as a broad incumbent defining the competitive landscape any new diagnostics entrant faces.
- Roche Diagnostics: Roche Diagnostics is the largest in-vitro diagnostics company globally, with cobas platforms and a deep assay menu across centralized and decentralized testing. Comparable as the dominant incumbent any diagnostics entrant must differentiate against.
- Becton, Dickinson and Company (BD): BD's Life Sciences and Diagnostic Systems segments include molecular diagnostics, sample preparation, and rapid testing products. Comparable as a broad incumbent with diversified diagnostics offerings and established clinical channel access.
Direct peers
- Qiagen: Qiagen is a molecular diagnostics and sample technologies company serving both clinical diagnostics and life science research customers. Comparable to Sensible Diagnostics as a more focused, science-driven diagnostics company whose model centers on consumables and assay kits.
Emerging players
- Mesa Labs: Mesa Labs develops and manufactures quality measurement and diagnostic instruments across clinical and industrial end markets, including sterilization indicators and cold-chain monitoring. Comparable as a smaller, niche diagnostics-adjacent company whose profile resembles what a young Sensible Diagnostics could look like once operational.
- GenMark Diagnostics: GenMark (now part of Roche) developed the ePlex system for syndromic molecular diagnostics prior to acquisition. Comparable as an emerging diagnostics player that built a focused molecular platform and ultimately achieved an incumbent exit — useful reference for a similarly named early-stage diagnostics venture.
Market position
Strengths3 records
Weaknesses5 records
Competitive moat1 record
Key risks4 records
Key highlights2 records
Customer concentration
Sensible Diagnostics social profiles
Digital presenceSensible Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sensible Diagnostics leadership team
Management profileNumber of profiles
Sensible Diagnostics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sensible Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sensible Diagnostics
What does Sensible Diagnostics do?
The company's core offerings cannot be determined from the available source data. The sourced material consists of a Google Sites placeholder page displaying an 'Under Construction' notice with no substantive product, service, or capability information. The company name 'Sensible Diagnostics' suggests an orientation toward diagnostic products, but no specific products or services are described in the input.
Is Sensible Diagnostics a public or private company?
Sensible Diagnostics is a private company. It is classified as unknown and is currently operating.
When was Sensible Diagnostics founded?
Sensible Diagnostics was founded in -1. It employs 11 to 50 people.
Where is Sensible Diagnostics based?
Sensible Diagnostics is headquartered in Los Angeles, United States, in the North America region.
Who are Sensible Diagnostics's main competitors?
Broad incumbents on record are Cepheid, bioMérieux, QuidelOrtho, Hologic, Abbott Diagnostics, Roche Diagnostics and Becton, Dickinson and Company (BD). Qiagen is listed as a direct peer. Emerging players are Mesa Labs and GenMark Diagnostics.
Does Sensible Diagnostics have an API?
No public API is recorded for Sensible Diagnostics.
What industry is Sensible Diagnostics in?
Sensible Diagnostics's product category is Clinical Diagnostics. Its primary akta.pro industry code is HLAGADAB, Method Development & Validation (ICH/USP). Its NAICS code is 325413.